The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double‐blind, placebo‐controlled trial
Abstract
Objective: To evaluate the safety and efficacy of adalimumab, a fully human recombinant IgG1 monoclonal antibody that specifically targets human tumor necrosis factor, in patients with active ankylosing spondylitis (AS). Methods: This was a multicenter, randomized (2:1 ratio), double‐blind, placebo‐controlled study to evaluate a subcutaneous injection of adalimumab, 40 mg every other week, compared with placebo for 24 weeks. The primary efficacy end point was the percentage of patients with a 20% response according to the ASsessment in Ankylosing Spondylitis International Working Group criteria for improvement (ASAS20) at week 12. Secondary outcome measures included the ASAS20 at week 24 and multiple measures of disease activity, spinal mobility, and function, as well as ASAS partial remission. Results: At week 12, 58.2% of adalimumab‐treated patients (121 of 208) achieved an ASAS20 response, compared with 20.6% of placebo‐treated patients (22 of 107) ( P < 0.001). More patients in the adalimumab group (45.2% [94 of 208]) than in the placebo group (15.9% [17 of 107]) had at least a 50% improvement in the Bath Ankylosing Spondylitis Disease Activity Index at week 12 ( P < 0.001). Significant improvements in the ASAS40 response and the response according to the ASAS5/6 criteria at weeks 12 and 24 were also demonstrated ( P < 0.001). Partial remission was achieved by more adalimumab‐treated patients than placebo‐treated patients (22.1% versus 5.6%; P < 0.001). Adalimumab‐treated patients reported more adverse events (75.0% versus 59.8% of placebo‐treated patients; P < 0.05), but there was no statistically significant difference in the incidence of infections. Most adverse events were mild or moderate in severity. Conclusion: Adalimumab was well‐tolerated during the 24‐week study period and was associated with a significant and sustained reduction in the signs and symptoms of active AS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Evaluation of Diagnostic Criteria for Ankylosing Spondylitis
Linden, S. V. D., Valkenburg, H. A., & Cats, A. (1984) · Arthritis & Rheumatism · doi:10.1002/art.1780270401 · Cited by 5,697
Garrett, S., Jenkinson, T., Kennedy, L. G., Whitelock, H., Gaisford, P., & Călin, A. (1994) · PubMed · Cited by 3,241
Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis
Lipsky, P. E., van der Heijde, D. M. F. M., St. Clair, E. W., Furst, D. E., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Weisman, M., Emery, P., Feldmann, M., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011303432202 · Cited by 2,996
Self-citationCălin, A., Garrett, S., Whitelock, H., Kennedy, L. G., O'Hea, J., MALLORIE, P. A., & Jenkinson, T. (1994) · PubMed · Cited by 2,329
(2001) · Classic Papers in Rheumatology · doi:10.3109/9780203214237-70 · Cited by 1,833
Weinblatt, M. E., Keystone, E. C., Furst, D. E., Moreland, L. W., Weisman, M. H., Birbara, C. A., Teoh, L. A., Fischkoff, S. A., & Chartash, E. K. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10697 · Cited by 1,757
Braun, J., Brandt, J., Listing, J., Zink, A., Alten, R., Golder, W., Gromnica-lhle, E., Kellner, H., Krause, A., Schneider, M., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08215-6 · Cited by 1,261
Self-citationKeystone, E. C., Kavanaugh, A. F., Sharp, J. T., Tannenbaum, H., Hua, Y., Teoh, L. S., Fischkoff, S. A., & Chartash, E. K. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20217 · Cited by 1,172
INFLIXIMAB AND METHOTREXATE IN THE TREATMENT OF RHEUMATOID ARTHRITIS
Ipsky, P. E. E. L., Illiam, E. W., Urst, D. A. E. F., Reedveld, C. B., Oachim, J., Alden, R. K., Osef, J., Molen, S. S., Eisman, M. I. W., Mery, P. A. E., et al. (2000) · Cited by 1,155
Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index.
Jenkinson, T., MALLORIE, P. A., Whitelock, H., KENNEDY, L. G., Garrett, S. L., & Călin, A. (1994) · PubMed · Cited by 981
Cited by
Magro, F., Gionchetti, P., Eliakim, R., Ardizzone, S., Armuzzi, A., Barreiro-de Acosta, M., Burisch, J., Gecse, K. B., Hart, A. L., Hindryckx, P., et al. (2017) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjx008 · Cited by 1,910
Braun, J., & Sieper, J. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60635-7 · Cited by 1,806
Self-citation2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis
van der Heijde, D., Ramiro, S., Landewé, R., Baraliakos, X., Van den Bosch, F., Sepriano, A., Regel, A., Ciurea, A., Dagfinrud, H., Dougados, M., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210770 · Cited by 1,568
Self-citationSieper, J., & Poddubnyy, D. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31591-4 · Cited by 1,333
Self-citationSecukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
Baeten, D., Sieper, J., Braun, J., Baraliakos, X., Dougados, M., Emery, P., Deodhar, A., Porter, B., Martin, R., Andersson, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505066 · Cited by 1,029
Self-citation2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis
Braun, J., van den Berg, R., Baraliakos, X., Boehm, H., Burgos-Vargas, R., Collantes-Estevez, E., Dagfinrud, H., Dijkmans, B., Dougados, M., Emery, P., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2011.151027 · Cited by 987
Self-citationVan Assche, G., Dignass, A., Reinisch, W., van der Woude, C. J., Sturm, A., De Vos, M., Guslandi, M., Oldenburg, B., Dotan, I., Marteau, P., et al. (2010) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2009.09.009 · Cited by 894
Adverse effects of biologics: a network meta-analysis and Cochrane overview
Singh, J. A., Wells, G. A., Christensen, R., Tanjong Ghogomu, E., Maxwell, L. J., MacDonald, J. K., Filippini, G., Skoetz, N., Francis, D. K., Lopes, L. C., et al. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008794.pub2 · Cited by 823
Inman, R. D., Davis, J. C., Heijde, D. V. D., Diekman, L., Sieper, J., Kim, S. I., Mack, M., Han, J., Visvanathan, S., Xu, Z., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23969 · Cited by 593
Self-citationvan der Heijde, D., Landewé, R., Einstein, S., Ory, P., Vosse, D., Ni, L., Lin, S. ‐., Tsuji, W., & Davis, J. C. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23471 · Cited by 549
Self-citationSieper, J., van der Heijde, D., Dougados, M., Mease, P. J., Maksymowych, W. P., Brown, M. A., Arora, V., & Pangan, A. L. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-201766 · Cited by 536
Self-citationHeijde, D. V. D., Landewé, R., Baraliakos, X., Houben, H., Tubergen, A. V., Williamson, P., Xu, W., Baker, D., Goldstein, N., & Braun, J. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23901 · Cited by 514
Self-citationVan Assche, G., Dignass, A., Bokemeyer, B., Danese, S., Gionchetti, P., Moser, G., Beaugerie, L., Gomollón, F., Häuser, W., Herrlinger, K., et al. (2013) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2012.09.005 · Cited by 463
Smolen, J. S., Braun, J., Dougados, M., Emery, P., FitzGerald, O., Helliwell, P., Kavanaugh, A., Kvien, T. K., Landewé, R., Luger, T., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-203419 · Cited by 447
Self-citationvan der Heijde, D., Salonen, D., Weissman, B. N., Landewé, R., Maksymowych, W. P., Kupper, H., Ballal, S., Gibson, E., Wong, R., & the Canadian (M03-606) study group and the ATLAS study group (2009) · Arthritis Research & Therapy · doi:10.1186/ar2794 · Cited by 413
Self-citationvan der Heijde, D., Deodhar, A., Wei, J. C., Drescher, E., Fleishaker, D., Hendrikx, T., Li, D., Menon, S., & Kanik, K. S. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210322 · Cited by 376
Self-citationvan der Heijde, D., Cheng-Chung Wei, J., Dougados, M., Mease, P., Deodhar, A., Maksymowych, W. P., Van den Bosch, F., Sieper, J., Tomita, T., Landewé, R., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31946-9 · Cited by 370
Self-citationVincent, F. B., Morand, E. F., Murphy, K., Mackay, F., Mariette, X., & Marcelli, C. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202545 · Cited by 356
Zochling, J. (2011) · Arthritis Care & Research · doi:10.1002/acr.20575 · Cited by 349
Navarro-Compán, V., Sepriano, A., El-Zorkany, B., & van der Heijde, D. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-221035 · Cited by 340
Self-citationHaibel, H., Rudwaleit, M., Listing, J., Heldmann, F., Wong, R. L., Kupper, H., Braun, J., & Sieper, J. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23606 · Cited by 316
Self-citationMinozzi, S., Bonovas, S., Lytras, T., Pecoraro, V., González-Lorenzo, M., Bastiampillai, A. J., Gabrielli, E. M., Lonati, A. C., Moja, L., Cinquini, M., et al. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1240783 · Cited by 308
Cytokines as Therapeutic Targets in Rheumatoid Arthritis and Other Inflammatory Diseases
Siebert, S., Tsoukas, A., Robertson, J., & McInnes, I. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009639 · Cited by 307
Song, I.-H., Hermann, K., Haibel, H., Althoff, C., Listing, J., Burmester, G., Krause, A., Bohl-Bühler, M., Freundlich, B., Rudwaleit, M., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.139667 · Cited by 285
Self-citationSfikakis, P. P. (2010) · Current Directions in Autoimmunity · doi:10.1159/000289205 · Cited by 275
Braun, J., Baraliakos, X., Deodhar, A., Baeten, D., Sieper, J., Emery, P., Readie, A., Martin, R., Mpofu, S., & Richards, H. B. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209730 · Cited by 273
Self-citationPoddubnyy, D., Hermann, K.-G. A., Callhoff, J., Listing, J., & Sieper, J. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204248 · Cited by 260
Self-citationHeiberg, M. S., Koldingsnes, W., Mikkelsen, K., Rødevand, E., Kaufmann, C., Mowinckel, P., & Kvien, T. K. (2008) · Arthritis Care & Research · doi:10.1002/art.23333 · Cited by 256
Lambert, R. G. W., Salonen, D., Rahman, P., Inman, R. D., Wong, R. L., Einstein, S. G., Thomson, G. T. D., Beaulieu, A., Choquette, D., & Maksymowych, W. P. (2007) · Arthritis & Rheumatism · doi:10.1002/art.23044 · Cited by 256
Self-citationMcGonagle, D. G., McInnes, I. B., Kirkham, B. W., Sherlock, J., & Moots, R. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-215356 · Cited by 254
Reilly, M. C., Gooch, K. L., Wong, R. L., Kupper, H., & van der Heijde, D. (2010) · Rheumatology · doi:10.1093/rheumatology/kep457 · Cited by 242
Self-citationvan der Heijde, D., Baraliakos, X., Gensler, L. S., Maksymowych, W. P., Tseluyko, V., Nadashkevich, O., Abi-Saab, W., Tasset, C., Meuleners, L., Besuyen, R., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32463-2 · Cited by 242
Self-citationHaanen, J., Ernstoff, M. S., Wang, Y., Menzies, A. M., Puzanov, I., Grivas, P., Larkin, J., Peters, S., Thompson, J. A., & Obeid, M. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.285 · Cited by 222
Sieper, J., Porter-Brown, B., Thompson, L., Harari, O., & Dougados, M. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-203559 · Cited by 184
Self-citationMonoclonal Antibodies: A Prospective and Retrospective View
Sivaccumar, J., Sandomenico, A., Vitagliano, L., & Ruvo, M. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867327666200219142231 · Cited by 14
37 Drugs that act on the immune system: cytokines and monoclonal antibodies
Vial, T., Descotes, J., Braun, F., & Behrend, M. (2007) · Side effects of drugs annual · doi:10.1016/s0378-6080(06)29037-8 · Cited by 3
Metadata
- Authors
- van der Heijde, D., Kivitz, A., Schiff, M. H., Sieper, J., Dijkmans, B. A. C., Braun, J., Dougados, M., Reveille, J. D., Wong, R. L., Kupper, H., & Davis, J. C.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2006-06-27
- Volume
- 54
- Issue
- 7
- Pages
- 2136-2146
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W1990305566
- Cited by
- 872
- References
- 37
- FWCI
- 33.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.